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ORIGINAL ARTICLE
Protease activation mutants elicit protective immunity
against highly pathogenic avian influenza viruses of
subtype H7 in chickens and mice
Ralf Wagner1, Gülsah Gabriel2,*, Matthias Schlesner2,#, Nina Alex1, Astrid Herwig2, Ortrud Werner3
and Hans-Dieter Klenk2
Protease activation mutants of the highly pathogenic avian influenza virus A/FPV/Rostock/34 (H7N1) have been generated that are
fully dependent on the presence of trypsin for growth in cell culture. Unlike wild-type virus, the mutants do not induce systemic
infection in chicken embryos and show low pathogenicity in both chicken embryos and adult chickens. Inactivated vaccines prepared
from the mutants protected chickens and mice very efficiently against infection with highly pathogenic wild-type virus in a
cross-reactive manner. The potential of these mutants to be used as veterinary and prepandemic vaccines will be discussed.
Emerging Microbes and Infections (2013) 2, e7; doi:10.1038/emi2013.7; published online 27 February 2013
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INTRODUCTION
Highly pathogenic avian influenza viruses (HPAIV) cause systemic
infections with lethal outcome in chickens, quail, geese and other
domestic birds. The disease is a major threat to the poultry industry,
since the economical damage resulting from the loss of millions of
birds may be enormous.1 The impact of these infections is drama-
tically illustrated by the H5N1 outbreak, with this virus now being
endemic in Southeast Asia and rapidly spreading to other parts of the
world.2,3
Although man has been thought for a long time not to be susceptible
to HPAIV infection, there is now increasing evidence that these viruses
can also cause disease in humans. This became quite obvious during
the H5N1 outbreak,4 but it was already observed before when avian
influenza A viruses of subtype H7, including HPAIV, were found to be
transmitted to man.5–7
The impact of these viruses for human health became most evident
during a large H7N7 outbreak in poultry in 2003, when over 300
primary and secondary human infections were observed in the
Netherlands. Most cases showed mild disease including conjunctivitis,
but there was one fatal outcome.8 These observations show that H7
like H5 viruses are able to cross the species barrier to man and that they
have therefore the potential to cause a pandemic.
Thus, there is clearly a need for vaccines against HPAIV both to
control outbreaks in birds and to be prepared for an emerging pan-
demic in humans. Several strategies have been employed for the gen-
eration of such vaccines. These include inactivated vaccines produced
by reverse genetic techniques,9–11 live attenuated cold-adapted
vaccines,12,13 vaccines based on recombinant adenovirus14 and DNA
vaccines.15 Because of the ongoing H5N1 outbreak, most of the studies
have focused on this subtype, whereas H7 viruses have attracted less
attention. Numerous inactivated human vaccines against H5N1
viruses have been developed and licensed worldwide. However, these
vaccines have so far been used only in limited numbers of subjects
mostly in clinical trials since there has been no actual H5N1 pandemic.
Further, protective H5N1-specific inactivated vaccines for the use in
poultry have been produced in China from seed strains generated by
reverse genetics.16,17 The experiences from China’s pioneering acti-
vities related to avian influenza vaccination have recently been
described.18
The prime determinant of the high virulence of HPAIV is the poly-
basic cleavage site of the haemagglutinin (HA) that allows activation
by furin. Since furin is a ubiquitous protease, this type of cleavage is
responsible for rapid virus spread resulting in systemic infection with
fatal outcome as opposed to local infection with low pathogenicity due
to restricted cleavability at monobasic cleavage sites.19 Replacement of
polybasic as well as monobasic cleavage sites by valine susceptible to
cleavage by elastase resulted in attenuated protease activation mutants
that have the potential to be used as live vaccines.20,21 Mutation at the
cleavage site of HA proved also to be useful for the production of
inactivated H5 HPAIV vaccines, since the large quantities of live virus
required for this purpose precludes the use of wild-type (WT) HPAIV
that would be extremely hazardous for the environment.10
We report here on the generation of highly attenuated H7 protease
activation mutants by reverse genetics. When used as inactivated
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vaccines, these mutants protected chickens and mice with high efficacy
from a lethal infection with H7 subtype viruses.
MATERIALS AND METHODS
Cells and viruses
Madin Darby canine kidney (MDCK) cells were cultured in minimal
essential medium (MEM) (Gibco, Gibco Life Technologies,
Darmstadt, Germany) supplemented with 10% fetal bovine serum
(Invitrogen, Invitrogen Life Technologies, Darmstadt, Germany).
Human embryonic kidney cells (293 cells) were maintained in
Dulbecco’s modified Eagle’s medium (Gibco) containing 10% fetal
bovine serum. Both cell lines were cultivated at 37 6C and 5% CO2. The
HPAIV strains A/FPV/Rostock/34 (H7N1) (FPV) and A/chicken/
Germany/R28/03 (H7N7) as well as the mouse-adapted variant of
the A/seal/Mass/80 (H7N7) strain (SC35M)22 were used.
Generation of FPV mutants
The establishment of a reversed genetics system for the rescue of FPV
has been described before.23 In brief, all eight viral gene segments were
isolated and cloned into the vector pHH21 for the RNA polymerase I-
driven transcription of viral RNA.24 Next, these eight plasmids were
cotransfected into 293 cells along with four additional plasmids for the
expression of the subunits of the influenza virus polymerase complex.
Two days post-transfection, 293 cell supernatants were passaged onto
MDCK cell monolayers for the efficient amplification of contained
recombinant viruses. Purification of rescued viruses was achieved by
three rounds of plaque passages on MDCK cells.
The two HA cleavage site mutants were produced by subjecting the
pHH21 construct carrying the WT HA gene to the Quickchange muta-
genesis procedure (Stratagene, Stratagene Agilent Technologies,
Waldbronn, Germany). The following primer pairs were used in this
approach: for mutant 1, GGG ATG AAG AAC GTT CCC GAA CCT
TCC AAA GGA AGA GGC CTG TTT GGC GCT ATA GCA GGG (fo)
and CCC TCT ATA GCG CCA AAC AGG CCT CTT CCT TTG GAA
GGT TCG GGA ACG TTC TTC ATC CC (re); for mutant 2: GGG
ATG AAG AAC GTT CCC GAA CCT TCC GCA GCA GCG AAA GGA
AGA GGC CTG TTT GGC GCT ATA GCA GGG (fo) and CCC TGC
TAT AGC GCC AAA CAG GCC TCT TCC TTT CGC TGC TGC GGA
GGT TCG GGA ACG TTC TTC ATC CC (re). For the generation of
the respective cleavage-mutant viruses, the resulting pHH21 constructs
were included in the above mentioned reverse genetics approach and
L-(tosylamido-2-phenyl)ethyl chloromethyl ketone-trypsin (Sigma,
Taufkirchen, Germany) was added to culture media at a final concen-
tration of 0.5 mg/mL. The genetic identity of rescued viruses was con-
firmed by sequencing of the complete HA gene.
Virus replication in cell culture
For growth curves, MDCK cell monolayers were inoculated at a mul-
tiplicity of infection (MOI) of 0.001 in phosphate-buffered saline
(PBS) containing 0.2% bovine serum albumin (BSA) (Invitrogen)
for 1 h. Unbound viruses were washed off and serum-free medium
containing 0.2% BSA was added. If desired, L-(tosylamido-2-pheny-
l)ethyl chloromethyl ketone-trypsin was added to a final concentra-
tion of 0.5 mg/mL. From then on, HA titres in the supernatants were
periodically monitored with chicken red blood cells (1% in saline).
For plaques assays, confluent MDCK cell monolayers in 2.5 cm
dishes (in six-well plates) were inoculated with 10-fold dilutions (in
PBS/0.2% BSA) of viruses for 1 h. Cells were washed and covered with
an overlay of MEM containing 0.5% purified agar (Oxoid Ltd, Wesel,
Germany), 0.2% BSA, and 0.001% DEAE-dextran. If applicable,
cultures were supplemented with L-(tosylamido-2-phenyl)ethyl
chloromethyl ketone-trypsin at a final concentration of 0.5 mg/mL.
Cells were incubated at 37 6C and 5% CO2, and plaques were visualized
3 days post-infection with 0.1% crystal violet in a 10% formaldehyde
solution.
Analysis of HA cleavage activation
MDCK cells were inoculated with viruses at a MOI of 5 for 1 h. Unbound
viruses were washed off with PBS and MEM was added. Four hours post-
infection, the cells were washed with PBS, and 15 mCi of Redivue Pro-Mix
L35S in vitro cell labelling mix (Amersham Pharmacia, Nuembrecht,
Germany) were added in 2 mL of methionine and cysteine free MEM.
If desired, trypsin was added to a final concentration of 1 mg/mL. After
12 h, cell supernatants were harvested and viruses collected by ultracen-
trifugation at 100 000 g for 2 h. Aliquots of these virus preparations were
subjected to a 10% sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis, and viral protein bands were visualized by fluorography.
Replication in embryonated chicken eggs
Eleven-day-old embryonated chicken eggs were inoculated into the
allantoic cavity with 2000 plaque forming units (pfu, as determined by
plaque assay on MDCK cells) of viruses. At given time points post-
inoculation, eggs were opened and checked for embryo viability. Next,
the allantoic fluid was collected and examined for virus titres by plaque
assay on MDCK cells.
Spread of viral infection to embryo tissues was addressed by in situ
hybridisation using digoxygenin (DIG)-labelled riboprobes specific
for the nucleoprotein gene of fowl plague virus (FPV-NP). The ribop-
robes were produced by run-off transcription of a fragment of FPV-
NP (nt. 1077–1442) that had been inserted into the vector Bluescript
KS1 (Stratagene). Transcription was carried out utilizing T7 RNA
polymerase and the DIG-RNA labelling Kit (Roche, Roche
Diagnostics GmbH, Mannheim, Germany). Riboprobes were purified
from the reaction mixture by means of the RNeasy-Kit (Qiagen,
Hilden, Germany) following the supplier’s protocol.
Sagittal embryo cryosections (20 mm) were fixated in 4% phos-
phate-buffered formaldehyde solution for 1 h at room temperature
(RT) and then washed three times with PBS for 10 min each. All
solutions were prepared from diethylpyrocarbonate-treated water.
Deproteination was achieved by proteinase K treatment (0.2 mg/mL)
for 10 min at RT. Sections were washed with water and post-fixated
with formaldehyde for 10 min (see above). Slides were then washed
with 100 mM glycin (in PBS) and PBS for 5 min each, transferred to a
solution of acetic anhydride (0.25% in 0.1 M triethanolamine, pH 8.0)
and incubated for 10 min at RT. Sections were washed in PBS, dehy-
drated in ethanol (50% and 70%) and air dried for 15 min. Next,
prehybridisation buffer (50% deionised formamide in 43SSC (0.6 M
NaCl in 0.06 M sodium citrate, pH 7.0)) was added for 1 h at 55 6C.
Prehybridisation buffer was removed and 150 mL of the DIG-labelled
riboprobe previously diluted 1 : 500 in hybridisation buffer (43SSC
containing 50% deionised formamide, 10% dextran solution,
13Denhardt’s solution, 0.1 mg/mL of yeast RNA, 0.1 mg/mL sheared
salmon sperm DNA, 10 mM ethylenediaminetetraacetic acid) were
applied for 16 h at 55 6C in a humid chamber. During incubation
sections were sealed with coverslips. Next, washes were done at 37 6C
with 23SSC, and 13SSC for 10 min each and samples subsequently
digested with RNase A (20 mg/mL) (Fermentas, St. Leon-Rot,
Germany) and RNase T1 (1 U/mL) (Fermentas) for 1 h at 37 6C (in
0.5 M NaCl, 1 mM ethylenediaminetetraacetic acid, 10 mM Tris/HCl,
pH 7.6). Additional washes at 37 6C with 0.53SSC, 0.23SSC for 10 min
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each followed. Finally sections were washed with 0.23SSC for 1 h at
60 6C.
Detection of bound DIG-riboprobes was achieved by means of
alkaline phosphatase-conjugated to anti-DIG Fab fragments and
5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium as a
chromogenic substrate (all reagents from Roche). To this end, cryo-
sections were washed with 0.3% Tween 20 for 5 min and 1% blocking
reagent for 30 min (both in 150 mM NaCl, 100 mM maleic acid, pH
7.5). Next, 250 mL of anti-DIG-alkaline phosphatase Fab fragments
(diluted 1 : 5000 in 1% blocking solution) were added for 30 min at
RT. Sections were washed twice for 15 min each with 0.3% Tween 20 in
maleic acid buffer and equilibrated in buffer 3 (100 mM NaCl, 50 mM
MgCl2, 100 mM Tris/HCl, pH 9.5). Chromogen solution of 250 mL
(45 mg/mL nitro blue tetrazolium, 0.175 mg/mL 5-bromo-4-chloro-
3-indolyl-phosphate in buffer 3) were applied and incubated in a
humid chamber at RT overnight in the dark. The reaction was stopped
with 10 mM Tris/HCl, pH 8.1 containing 1 mM ethylenediaminete-
traacetic acid. Embryonic tissues were finally counterstained with hae-
matoxylin–eosin.
Pathogenicity in chicken
The animal experiments were performed at the Friedrich-Loeffler-
Institute, the German federal research institute for animal health,
according to the guidelines of the German animal protection law.
All animal protocols were approved by the state authorities of
Mecklenburg-Vorpommern. Work with FPV and strain A/chicken/
Germany/R28/03 (H7N7) was conducted under biosafety level 3 con-
ditions. The virulence of influenza A viruses for chickens was esti-
mated using the intravenous pathogenicity index (IVPI) test as
follows: fresh infective allantoic fluid with a HA titre .24 was diluted
1 : 10 in sterile isotonic saline and 0.1 mL of the diluted virus was
injected intravenously into each of ten 6-week-old specific patho-
gen-free (SPF) chickens. Birds were examined at 24-h intervals for
the following 10 days. At each observation, each bird was scored 0 if
normal, 1 if sick, 2 if severely sick and 3 if dead. The judgment of sick
and severely sick birds is a subjective clinical assessment. Normally,
‘sick’ birds would show one and ‘severely sick’ birds more than one of
the following signs: respiratory involvement, depression, diarrhea,
cyanosis of the exposed skin, oedema of the face and/or head and
nervous signs. The IVPI is the mean score per bird per observation
over the 10-day period. An index of 3.00 means that all birds died
within 24 h, and an index of 0.00 means that no bird showed any
clinical sign during the 10-day observation period. Any influenza A
virus, regardless of subtype, giving a value of greater than 1.2 in an
IVPI test, is considered to be a HPAI virus.25
Preparation of formalin-inactivated vaccine
Eleven-day-old embryonated chicken eggs were inoculated with
recombinant viruses via the allantoic route (40 eggs per virus species).
Allantoic fluids were harvested 36 h post inoculation and centrifuged
for 15 min at 5000 g to remove debris. Next, virus was pelleted by
centrifugation for 12 h at 65 000 g. Virus sediments were thoroughly
resuspended in 2 mL of PBS containing a protease inhibitor cocktail
(Calbiochem, Schwalbach, Germany) and further purified by sucrose
step gradient ultracentrifugation (bottom 60%; top 20%) in a
Beckman SW 41 rotor at 120 000 g for 8 h. The interface was
removed from the gradient, and virus was pelleted for 8 h at
100 000 g in the same rotor. Virus pellets were resuspended to homo-
geneity in 2 mL of PBS containing protease inhibitor. The bulk of the
material was inactivated at a protein concentration of 1 mg/mL with
0.025% formalin at 4 6C for 4 days. After this treatment, inactivated
virus was concentrated by ultracentrifugation and pellets recovered in
1 mL of PBS with protease inhibitor. Aliquots were taken for purity
analysis by Coomassie-stained sodium dodecyl sulfate–polyacryla-
mide gel electrophoresis and for calculating the HA/total viral protein
ratio. At different stages of purification, the protein concentrations of
the virus preparations were determined by means of the bicinchoninic
acid (BCA)-protein assay (Pierce, Rockford, United States) following
the manufacturer’s instructions.
Immunisation and protective efficacy in adult chickens
A vaccine formulation was produced by diluting 600 mL of purified
virus suspension (corresponding to about 150 mg of HA) in 1.8 mL of
PBS and by subsequently adding 2.4 mL of complete Freund’s adjuv-
ant. The resulting emulsion was mixed thoroughly and then injected
into the pectoral muscles of SPF chickens 5 months of age at a dose of
0.5 mL per animal. Twenty-two days post-vaccination, animals were
challenged by intranasal inoculation with 107.9 50% egg infectious
dose (EID50) of the HPAIV strain A/chicken/Germany/R28/03
(H7N7). As a control, unvaccinated chickens were included in the
trial which received the same dose of challenge virus. Blood samples
were taken for the determination of serum haemagglutination inhibi-
tion antibody titres at days 0, 9, 14 and 21 post-vaccination and days 7,
14 and 19 post-challenge. Animals were monitored for the develop-
ment of clinical symptoms, mortality and shedding of the challenge
virus.
Immunisation and protective efficacy in mice
The animal experiments were performed according to the guidelines of
the German animal protection law. All animal protocols were approved
by the relevant German authority, the Regierungspräsidium Giessen.
Handling of the SC35M virus was conducted in compliance with bio-
safety level 3 requirements. Groups of female 5-week-old Balb/C mice
(Charles River, Sulzfeld, Germany) were intramuscularly immunized
with preparations of formalin inactivated FPV mutant 1 containing 7
or 15 mg HA with or without Freund9s adjuvant in a 1 : 1 dilution. Four
weeks after immunisation, mice were challenged intranasally with 100
median lethal doses (LD50) of SC35M (H7N7) under anesthesia set by
an intraperitoneal injection of ketamine (100 mg/kg) and xylazine
(10 mg/kg). Mice were observed for weight loss and signs of disease
for 2 weeks after immunisation and challenge, respectively.
RESULTS
Generation of FPV cleavage site mutants
The sequence at the cleavage site of FPV-HA was mutated in order
to generate a motif that is no longer accessible to processing by the
ubiquitous cellular protease furin.26 Two different HA mutants
were generated (Figure 1A). The first one (Mut1) represents a
cleavage site typically found in mammalian and low-pathogenic
avian influenza viruses.19 In the second mutant (Mut2) the cleavage
site motif of Mut1 was elongated by the addition of three alanine
residues to restore the full length of the WT cleavage site. Using a
reverse genetics system, these mutant HA sequences were stably
incorporated into recombinant viruses.24 We have recently
developed such a system allowing us to generate recombinant
FPV.23 Mutant viruses were rescued in the presence of trypsin in
cultured cells and amplified in the allantoic cavity of embryonated
chicken eggs. The correct genetic identity of the rescued viruses was
finally confirmed by sequencing of the HA genes.
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Replication in MDCK cells
First, we looked at the replication of the virus mutants in MDCK cells.
Growth curves showed that, in accordance with the existing furin
recognition motif in HA, WT virus was able to replicate in these cells
in the absence of exogenously added trypsin. In contrast, replication of
both cleavage site mutants was found to be strictly dependent on the
presence of trypsin in the culture medium (Figure 1B). The situation
was the same when the ability of these viruses to produce plaques in the
MDCK cell monolayer was assayed. Virus mutants were unable to
spread from cell to cell in the absence of trypsin, while large plaques
were obtained when trypsin was added to the medium (Figure 1C).
Again, production of plaques with WT viruses was identical irrespec-
tive of the presence of trypsin. The growth restrictions of the virus
mutants were due to the lack of proteolytic activation of HA in the
absence of trypsin. This became clear when we examined the protein
pattern of virus released from MDCK cells that had been infected with
mutants at a high multiplicity of infection. Only in cells treated with
trypsin, the HA precursor is cleaved into its subunits HA1 and HA2
(Figure 2). No cleavage products are detectable if trypsin was omitted.
Due to its accessibility to cleavage by the cellular protease furin, for
A
FPV-HA cleavage mutants:
WT-HA
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Mut2 (insertion)
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C
Figure 1 Characterisation of FPV mutants. (A) Cleavage site motifs of WT and mutant viruses. The WT cleavage site sequence of FPV and the two mutants produced for
the generation of recombinant viruses are depicted. Asterisks indicate the site of cleavage. (B and C) Replication of viruses in MDCK cell culture in the absence and
presence of trypsin. (B) Cells were inoculated at a MOI of 0.001. At the indicated time points, culture supernatants were monitored for HA titres using chicken red blood
cells. (C) Spread of virus infection traced by plaque formation. Monolayers seeded in six-well plates (diameter per well: 35 mm) were inoculated with the indicated
viruses and covered with an agarose-containing medium overlay. At 3 days post-infection, plaques were visualized by staining cell monolayers with a crystal violet
solution.
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WT HA, there is no need for trypsin to achieve proteolytical proces-
sing. Hence, the mutations introduced into the HA sequence totally
abrogated furin-mediated proteolytic activation. As a consequence,
replication of the mutant viruses in MDCK cell culture is strictly
dependent on exogenously added proteases targeting monobasic
cleavage sites, such as trypsin.
Replication and pathogenicity in embryonated chicken eggs
Growth to high titres in embryonated chicken eggs is a key require-
ment for a virus designated to serve as a candidate seed strain for
vaccine production. Therefore, we examined the replication of FPV
mutants in this system. Thirty hours post-inoculation into the allan-
toic cavity, allantoic fluids were harvested and monitored for viral
titres by plaque assay on MDCK cells in the presence of trypsin. It
turned out that all three virus types reached almost the same titres in a
range of 5.23108–6.43108 pfu/mL (Figure 3A). Thus, while changes
in the HA cleavage site motif drastically inhibit growth of mutant
viruses in cell culture, replication in embryonated chicken eggs is
not affected.
We next examined the pathogenicity of our set of viruses in embryo-
nated chicken eggs by comparing the survival rates of embryos at
different time points after inoculation. Embryos from WT FPV-
infected eggs started to die at 18 h post-infection. Twenty-four hours
post-infection, all embryos within this group were dead (Figure 3B). In
contrast, embryos in eggs infected with the mutant viruses did not die
until 48 h following inoculation. Accordingly, by solely converting the
HA cleavage site motif, FPV can be efficiently attenuated and trans-
formed into a non-pathogenic avian virus. This finding was confirmed
when we analysed the spread of the infection within the embryo tissues
by in situ hybridisation. In this assay, a DIG-labelled RNA probe
specific for the FPV-NP segment was used to detect viral replication
in embryo cryosections. All organs of WT-infected embryos showed
clear signs of infection (Figure 4). The infection was confined to the
endothelia of blood vessels as already reported previously.27 However,
no evidence of infection was detected in embryo tissues from eggs
infected with the mutants indicating that these viruses are unable to
cross the chorio-allantoic membrane, a typical feature of low patho-
genic avian influenza viruses (LPAIV).28 Taken together, these results
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Trypsin
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Figure 2 Analysis of cleavage activation of HA. MDCK cells were infected at a MOI
of 5 and incubated in 35S-methionine/cysteine containing medium in the absence
or presence of trypsin. After 12 h, metabolically labelled progeny viruses were
collected from the cell supernatants by ultracentrifugation and aliquots of the virus
preparations were applied to a 10% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis. Protein bands were visualized by fluorography. The uncleaved
HA precursor (HA0) and the cleavage products HA1 and HA2 are indicated.
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Figure 3 Pathogenicity and virus yields in embryonated chicken eggs. (A) Virus yields in allantoic fluids 30 h post-inoculation. (B) Mortality of embryos over time.
Eleven-day-old embryonated eggs were inoculated by the allantoic route with 2000 pfu/egg. At the indicated time points post-inoculation, eggs were opened and
checked visually for viability of embryos. The survival rates are given as per cent values based on the total number of eggs infected per virus species.
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demonstrate that, although the FPV mutants can grow to high titres in
the allantoic cavity of chicken eggs, they otherwise behave as typical
LPAIV which fail to infect and to rapidly kill chicken embryos.
Pathogenicity in adult chickens
To employ these FPV mutants as seed strains for the production of
influenza vaccines, it is of crucial importance to make sure that their
non-pathogenic phenotype in cell culture and embryonated chicken eggs
is retained upon infection of adult animals. To prove this, three groups
of 10 chickens each were infected intravenously. All 10 animals infected
with WT viruses developed typical severe signs of fowl plague and seven
out of ten died. In contrast, all of the chickens infected with the virus
mutants survived. Only one animal suffered transiently from mild diar-
rhea and slight depression. The other animals showed no disease symp-
toms, thus providing striking evidence for the low pathogenicity of the
mutant viruses (Figure 5). The intravenous pathogenicity indices of the
viruses were 2.34, 0.0 and 0.07 for WT, Mut1 and Mut2, respectively.
Hence, owing to their capability for high yield growth in embryo-
nated chicken eggs on the one hand and their complete attenuation in
chicken embryos and adult birds on the other hand, the engineered
FPV mutants are perfectly suited for the safe production in bulk
amounts that is a key prerequisite for vaccine manufacturing.
Immunogenicity and protective efficacy of formalin-inactivated
vaccine in chickens
Next, the potential of FPV mutant 1 to serve as antigenic component
of an inactivated vaccine for the protection of adult chickens from an
HPAIV challenge was investigated. To this end, the virus was grown in
large scale in embryonated chicken eggs and purified from allantoic
fluids by centrifugation through a sucrose gradient. Inactivated whole-
virus vaccine was prepared by formalin treatment. The absence of any
residual infectivity in the inactivated virus preparation was confirmed
by plaque assay on MDCK cells (data not shown). Aliquots of the
purified vaccine preparation containing approximately 15 mg of HA
protein were mixed with Freund’s adjuvant and employed for the
intramuscular immunisation of a group of nine SPF chickens. On
day 22 post-vaccination, the birds were challenged oculo-nasally with
107.9 EID50 of the HPAIV A/chicken/Germany/R28/03 (H7N7), a
virus that has an intravenous pathogenicity index in chickens of
2.93. Additionally, three unvaccinated birds were included in the chal-
lenge experiment as a control. Over a period of 40 days post-vaccina-
tion, the animals were monitored for clinical symptoms of infection
and the development of a H7N7-specific serum antibody response as
determined by hemagglutination inhibition (HI) test. No serum anti-
bodies directed against the H7N7 virus were found in blood samples
taken before vaccination. At day 9 post-vaccination, however, specific
HI titres were detectable in the serum of all vaccinated chickens which
reached peaks of 211 in vaccinated animals at the end of the experiment
(Table 1). No such antibody titres were found in non-vaccinated con-
trol animals. Apart from a mild form of diarrhea at day 3 post-infec-
tion, none of the vaccinated animals showed signs of avian influenza
and all chickens stayed perfectly healthy until the end of the trial. In
one animal, transient shedding of H7N7 virus was detected in oro-
pharyngeal and cloacal swabs. In contrast, unvaccinated control ani-
mals rapidly developed typical symptoms of severe avian influenza
(head edema, ruffled feathers, diarrhea, depression) and died at day
3 post-infection.
Taken together, these results clearly demonstrate that the inacti-
vated FPV mutant 1 has the potential to elicit a high-titre antibody
response that completely protects birds from a lethal challenge even
with another HPAIV strain of the H7 subtype.
Immunogenicity and protective efficacy of formalin-inactivated
vaccine in mice
Further, we investigated the potential of the inactivated mutant 1
vaccine for its ability to cross-protect against a lethal challenge with
WT
Blood vessel Lung Stomach
Mut1
Mut2
Figure 4 Spread of virus infection to embryonic tissues. Eleven-day-old embryonated chicken eggs were inoculated as outlined in the legend to Figure 3. At 48 h post-
inoculation, embryos were removed for the preparation of sagittal cryosections. Virus infection of the depicted tissues was detected by means of in situ hybridisation
employing a digoxygenin-labelled riboprobe specific for the FPV-NP gene. Embryonic tissues were visualized by common haematoxylin–eosin staining (magnification:
363).
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another related but antigenically distinct H7 virus, the mouse-adapted
strain SC35M.29 Therefore, groups of mice (n55) were immunized
intramuscularly according to the following protocol: (i) one dose of
non-adjuvanted vaccine containing 7 mg of HA; (ii) one dose of vac-
cine containing 7 mg HA in Freund’s adjuvant; (iii) two doses of
adjuvanted vaccine containing 7 mg HA and administered 2 weeks
apart; and (iv) one dose of adjuvanted vaccine containing 15 mg HA.
As a control, one group remained unvaccinated. The vaccine was
tolerated very well by all animals irrespective of the immunisation
scheme as judged from body weight measurements (Figure 6A).
Four weeks after the single immunisation or two weeks after the se-
cond immunisation, mice were challenged intranasally with 100LD50
of SC35M. During the subsequent observation period, all vaccinated
animals survived indicating that they were robustly protected against a
lethal challenge with SC35M (Figure 6B). Groups receiving one dose of
7 mg HA either with or without adjuvant exhibited a temporary weight
loss of approximately 20%. Weight loss was lower (app. 10%) in those
groups having received either one adjuvanted dose of 15 mg HA or two
adjuvanted doses 7 mg HA. All control mice succumbed to infection
within 5 days post-challenge.
Accordingly, the results for vaccine efficacy in mice very closely
correlated with those observed in chickens. Taken together, these
data clearly demonstrate that the FPV-based vaccine is highly
effective to induce cross-protection in animals against a lethal
infection by an antigenically different influenza strain of the same
subtype.
DISCUSSION
Proteolytic activation of influenza virus HA by cleavage into its sub-
units HA1 and HA2 has long been known to be a prime determinant of
virulence.19,30 Additional factors either encoded by the virus itself or
provided by the host cell significantly contribute to host restriction,
transmission and pathogenicity, and therefore, influenza virulence
clearly is to be regarded a multifactorial trait.31,32 In terms of proteo-
lytic activation, two major classes of viruses can be distinguished.
LPAIV contain HA with monobasic cleavage motifs susceptible to
trypsin-like proteases present only in the respiratory or gastro-intest-
inal tract. In contrast, the HA of HPAIV has a multibasic cleavage site
that is activated by the ubiquitous cellular protease furin, thus allow-
ing for a systemic spread of the infection.19,26,33 Attempts to confer
high pathogenicity by solely introducing a multibasic cleavage site into
the HA of LPAIV of H3- and H5-subtypes have so far proved unsuc-
cessful,34,35 clearly indicating that a multibasic HA cleavage site alone
is not per se sufficient for the development of a HP phenotype for these
subtypes.
In this study, we have generated and characterized protease activa-
tion mutants of the HPAIV A/FPV/Rostock/34 (H7N1). Using a
reverse genetics approach, the long loop between HA1 and HA2 con-
taining the multibasic cleavage site was converted into either a short
loop (mutant 1) or into a long loop (mutant 2), each containing a
single arginine as cleavage motif. The rationale for creating these dif-
ferent mutants was to trace potential impacts of HA cleavage loop
conformation and accessibility on proteolytic activation and resulting
viral pathogenicity.36 Replication and pathogenicity of the mutants
were analysed in cell culture, chicken embryos and chickens. In con-
trast to WT FPV, both virus mutants exhibited a classical low patho-
genic phenotype as judged from the following findings: (i) cleavage
activation and multistep replication in cell culture were fully depen-
dent on the presence of exogenously added trypsin; (ii) growth in
embryonated chicken eggs was identical to that observed for typical
LPAIV; and (iii) the IVPIs of the mutants in chickens were 0.0 (mutant
1) and 0.07 (mutant 2) as compared to 2.34 of WT virus. This clearly
reveals that the multibasic cleavage site is the key virulence factor of
FPV and that its removal is sufficient to convert FPV into a virus with
classical LPAIV phenotype. No significant differences regarding repli-
cative properties or pathogenicity were detected between mutants 1
and 2 indicating that length and conformation of the cleavage loop
have no effect on the accessibility of the monobasic cleavage site to the
activating protease.
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Figure 5 Pathogenicity of FPV mutants in adult chicken. Three groups of ten
6-week old SPF chickens each were inoculated intravenously with fresh infective
allantoic fluid (HA titre .24) containing WT, Mut1 or Mut2 viruses. From then on,
birds were examined at 24-h intervals for the following 10 days. At each obser-
vation, the birds are examined for clinical signs of disease and scored 0 if normal,
1 if mildly sick, 2 if severely sick and 3 if dead (for details, see the section on
‘Materials and methods’). The intravenous PI is the mean score of birds per group
over the entire observation period. PI, pathogenicity index.
Table 1 Immunogenicity and protective efficacy in chickens of the inactivated vaccine prepared from FPV mutant 1
HI-GMTa (log 2) Clinical manifestationsb
Days post vaccination Days post challenge Severe symptoms or
death Survival
0 9 14 21 7 14 19
Vaccinated animals 0 5.23 (1.6) 7.07 (1.9) 8.51 (2.0) 10.54 (0.5) 10.19 (0.8) 11.0 (0.0) 0 100
Control animals 0 — — — 0 — — 100 0
A group of nine SPF-chickens was immunized intramuscularly with an adjuvanted vaccine preparation containing approximately 15 mg HA per dose. Three control animals
remained unvaccinated in a separate cage. At day 22 post-vaccination, all animals were challenged with 107.9 EID50 units of influenza A/chicken/Germany/R28/03 (H7N7).
For the following 19 days, the animals were monitored for signs of infection (such as fever, oedema, ruffled feathers, diarrhoea, depression), mortality and shedding of the
challenge virus. Serum antibodies were determined by HI assay.
a Geometric mean values of HI-titres and standard deviations (in brackets). Titres are determined with virus strain A/chicken/Germany/R28/03 (H7N7).
b Percentage of animals.
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Virus yields of WT and mutant FPV obtained in allantoic fluids
were within the same range, indicating that the extensive loss of patho-
genicity does not interfere with efficient replication in embryonated
chicken eggs. Very importantly, during multiple passages in embryo-
nated chicken eggs, we never observed viral escape mutants, indicating
that the introduced cleavage site mutations are very stable. Because of
these properties, we concluded that the FPV cleavage mutants might
be promising candidates for safe and large-scale production of an
avian influenza vaccine. In order to prove this concept, an inactivated
vaccine produced from egg-grown FPV mutant 1 was prepared and
used for the immunisation of chickens. Three weeks after vaccination,
the animals were challenged with a lethal dose of the HPAIV isolate A/
chicken/R28/03 (H7N7) that shares about 93% sequence identity in
the HA protein with FPV. All vaccinated animals were fully protected
against the challenge with this non-homologous virus and survived
without showing signs of severe disease. In contrast, all non-vacci-
nated animals developed classical fowl plague symptoms and died
within 3 days following challenge. These results clearly demonstrate
that an inactivated vaccine based on a protease activation mutant of
FPV as seed virus can be readily produced in chicken eggs and very
efficiently protects chickens from severe clinical disease and death
caused by a non-homologous but related HPAIV.
We also tested the efficacy of the vaccine in a mammalian challenge
system by analysing its ability to protect mice from lethal infection with
SC35M virus (H7N7).29 All HA-antigen dosages and formulations tested
protected mice from a lethal challenge while all non-vaccinated animals
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Figure 6 Immunisation of mice with formalin-inactivated vaccine prepared from FPV mutant 1 (H7N1) and subsequent challenge with 100LD50 of SC35M (H7N7).
Groups of five mice each were immunized intramuscularly as indicated in the boxes. An unvaccinated group was used as a control. Mice were monitored for 14 days
after immunisation (A) and after challenge (B) for weight loss and signs of disease.
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died within 5 days after infection. As the HAs of FPV mutant 1 and
SC35M display only 85% overall sequence homology, these results
clearly demonstrate that the vaccine elicits a potent crossreactive
immune protection. It can also be concluded from these observations
that the vaccine is not restricted to the use in birds, but that it may also
be applicable to a broader range of species. Hence, our data strongly
indicate that FPV protease activation mutants constitute very useful seed
strains for the rapid and large-scale production of safe and efficient H7-
specific vaccines in a (pre)pandemic situation.
In a more general scenario, the FPV cleavage mutants might also
represent a powerful alternative to strain A/PR/8/34 that is currently
used almost exclusively as donor of the internal viral genes for the
generation of reassortant seed strains on which human influenza vac-
cines are based.37,38 FPV grows to very high titres in eggs as well as in
cell cultures, and as shown here, the yields of the mutants are similar to
those obtained with WT virus. In this context, it is important to note
that while most influenza vaccines are still produced in embryonated
chicken eggs, several cell culture-based vaccine products have recently
been licensed for seasonal as well as for pandemic indications.39–41
Therefore, the use of high-growth FPV reassortants with HA and
NA proteins of circulating viruses generated on the basis of the clea-
vage mutants might be of considerable advantage especially in a pan-
demic situation where timely availability of large numbers of vaccine
doses is of utmost importance for the immediate and efficient protec-
tion of vulnerable population groups.
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